Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), a European healthcare company focused on human genetics and personalized products, announced the U.S. market launch of its new MGT Plus methylation test. The launch, in collaboration with U.S. partner 10X Health, aims to strengthen their international cooperation in genetic analysis and longevity. This move comes as the global direct-to-consumer testing market is projected to grow from approximately $4.7 billion in 2025 to over $16.0 billion by 2033, with genetic testing representing the largest segment at over 40% of the market.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It influences the function and processing of biological molecules, including vitamins and neurotransmitters. While existing commercial tests analyze a limited number of genes, MGT Plus covers a total of 27 genes, offering a more comprehensive view of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. This broader scope provides more precise insights into key biochemical processes, enabling more personalized prevention and health strategies.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of the expanded test: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health."
The U.S. market is particularly attractive due to its leading role in the genetic testing sector, accounting for about 50% of the global market volume in 2025. This growth is driven by increasing consumer interest in personalized health information and preventive care. Novogenia's expansion into the U.S. with MGT Plus positions the company to capitalize on this trend, offering a more comprehensive methylation test to a broader audience.
Novogenia AG, headquartered in Munich, Germany, operates its own laboratory for genetic analyses used in diagnosis, treatment, and prevention of diseases, as well as in the production of tailored nutritional supplements and cosmetics. The company also partners with healthcare professionals to optimize patient care based on genetic predispositions. With this new launch, Novogenia continues to broaden its international product portfolio and reinforce its presence in the growing personalized medicine market.
